Waters Corporation (WAT) - Form 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2000. Waters Corporation is the world's largest manufacturer of high performance liquid chromatography (HPLC) instruments and a leader in mass spectrometry (via Micromass) and thermal analysis (via TA Instruments). The company operates in the analytical instrument industry, serving life science, pharmaceutical, and polymer analysis sectors.
Key Financial Metrics
(Figures in thousands, except per share data)
| Metric | Q2 2000 | Q2 1999 | YTD 2000 | YTD 1999 |
|---|---|---|---|---|
| Net Sales | $195,276 | $172,280 | $375,917 | $332,642 |
| Gross Profit | $124,077 | $108,568 | $238,305 | $208,308 |
| Gross Margin | 63.5% | 63.0% | 63.4% | 62.6% |
| Operating Income | $50,700 | $41,976 | $92,360 | $76,481 |
| Net Income | $37,255 | $28,906 | $67,574 | $51,880 |
| Diluted EPS | $0.55 | $0.43 | $1.00 | $0.78 |
| Cash from Operations (YTD) | $83,974 (vs $75,884 YTD 1999) | |||
| Long-Term Debt | $2,915 | $81,105 (Dec 31, 1999) | ||
| Cash & Equivalents | $2,461 | $3,803 (Dec 31, 1999) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% year-over-year for both the quarter and the six-month period. Excluding currency effects, sales grew 15%.
- Profitability: Net income rose 29% for the quarter and 30% year-to-date, driven by sales growth, manufacturing efficiencies, and a lower effective tax rate (26% vs 27%).
- Debt Reduction: Long-term debt decreased significantly from $81.1 million at year-end 1999 to $2.9 million as of June 30, 2000, due to aggressive debt repayments funded by operating cash flow.
- Interest Expense: Net interest expense dropped 86% for the quarter and 81% year-to-date due to lower average debt levels.
- Product Performance: Time-of-flight mass spectrometry sales grew over 50% in the quarter, driven by demand in drug discovery and proteomics.
Outlook, Risks, and Unusual Items
- Stock Split: On July 13, 2000, the Board approved a two-for-one stock split (100% stock dividend) payable on or about August 25, 2000. Financial data in this filing has not been adjusted for the split.
- Strategic Alliance: In June 2000, Waters formed an alliance with Variagenics, Inc., paying $10.5 million for a minority equity stake and a license to manufacture genetic variance reagent kits. Future milestone payments up to $4 million and royalties are possible.
- Legal Proceedings: The company is involved in several patent disputes (including with Perkin-Elmer, Hewlett-Packard, Cohesive Technologies, and Viscotek). Management believes it has meritorious arguments and that outcomes will not be material to the company.
- Accounting Changes: Implementation of SAB 101 (Revenue Recognition) has been delayed to the fourth quarter of 2000. The impact is currently being determined.
- Liquidity: Management believes existing cash, operating cash flow, and available credit lines are sufficient to fund working capital and debt service. No dividends are planned.
Investor Verification Checklist
- Verify the impact of the pending two-for-one stock split on share count and per-share metrics for future reporting.
- Monitor the status of the Variagenics alliance and potential future milestone payments.
- Review the resolution of ongoing patent litigation, particularly the Perkin-Elmer appeal and HP patent challenges.
- Assess the impact of the delayed SAB 101 implementation on future revenue recognition policies.
- Confirm the sustainability of the 63%+ gross margin given the mix of high-growth mass spectrometry products.